How well does Tabrecta(Capmatinib) work?

Demonstrated efficacy in treatment-naïve and previously treated patients.

Treatment Efficacy

The efficacy of TABRECTA was established in the GEOMETRY mono-1 clinical trial. In patients with metastatic MET exon 14 skipping NSCLC who were treatment-naïve, the therapy achieved an overall response rate of 68%, with a median duration of response of 16.6 months. For patients who had received prior systemic therapy, the overall response rate was 44%, with a median duration of response of 9.7 months. This demonstrates significant anti-tumor activity in this genetically defined patient population.